Antibody-drug Conjugates & Bioconjugates
PUBLICATIONS ON SMARTAG® TECHNOLOGY
Barfield, R.M. et al. (2020) A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels. Molecular Cancer Therapeutics. 19: 1866-1874.
Bauzon, M. et al. (2019) Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells. OncoImmunology. doi: 10.1080/2162402X.2019.1565859
Drake, P. et al. (2018) CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models. Molecular Cancer Therapeutics. 17:161-168.
Botzanowski, T. et al. (2017) Insights from native mass spectrometry approaches for top- and middle-level characterization of site-specific antibody-drug conjugates. MAbs. 9(5):801-811. doi: 10.1080/19420862.2017.1316914.
York, D. et al. (2016) Generating aldehyde-tagged antibodies with high titers and high formylglycine yields by supplementing culture media with copper(II). BMC Biotechnology. 16:23. doi: 10.1186/s12896-016-0254-0.
Drake, P. and D. Rabuka. (2015) An emerging playbook for antibody-drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety. Current Opinion in Chemical Biology. 28:174-180.
Drake, P. et al. (2014) Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjugate Chemistry 25, 1331-1341